Hematuria Treatment Market Size, Share, and Industry Analysis, By Type (Gross Hematuria, Microscopic Hematuria, Idiopathic Hematuria, and Others), By Indication (UTI, Kidney Stones, Tumor in Kidney or Bladder, and Benign Prostate Enlargement), By Drug Type (Antibiotics, Diuretics, Alpha-blockers, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2026-2034

The global hematuria treatment market size was valued at USD 1.14 billion in 2025. The market is projected to grow from USD 1.17 billion in 2026 to USD 1.5 billion by 2034, exhibiting a CAGR of 3.14% during the forecast period.

Hematuria is a condition in which blood is present in the urine. The hematuria treatment market is witnessing significant growth due to the increasing prevalence of underlying conditions such as UTIs, kidney stones, bladder cancer, genetic disorders, and benign prostate enlargement glands. The most common cause of hematuria in women is UTI, and in men, benign prostate enlargement is the most common cause.

Hematuria treatment consists of medications and clinical procedures. Antibiotics are used to cure UTIs and diuretics are prescribed for kidney stones and benign prostate enlargement glands in men. There are no drugs available in the market to cure the condition and drugs are only available to treat the symptoms.

Hematuria Treatment Market Drivers

Rising Awareness of Urological Diseases to Propel the Market Growth

The rising prevalence of urological conditions such as UTIs, kidney stones, bladder cancer, and benign prostatic hyperplasia has prompted government bodies and healthcare institutions to cultivate awareness and explore novel treatment modalities for these diseases.

• For instance, in May 2024, Cxbladder designated May month as the bladder cancer awareness month. This initiative aimed to raise awareness about hematuria and its associated causes, thereby providing valuable information to the public.

Download Free sample to learn more about this report.

Hematuria Treatment Market Restraints

Side Effects of Treatment May Limit the Adoption of Drugs Hindering the Market Growth

The side effects of hematuria treatments, particularly from invasive procedures and aggressive medications, can hamper patients from seeking or continuing care. The fear of adverse effects reduces the adoption of these drugs, ultimately limiting market growth.

• For instance, in May 2023, according to an article published by NCBI, the common adverse effects of thiazides are electrolyte abnormalities such as hyponatremia, hypokalemia, and metabolic alkalosis.

Hematuria Treatment Market Opportunities

Growing Adoption of Telemedicine and Digital Health Solutions to Improve Treatment Access

The growing adoption of telemedicine and digital health solutions enhances access to hematuria treatment, especially in remote areas. The innovation allows for timely monitoring and patient management, improving outcomes and expanding reach to a larger population. The convenience and accessibility of these technologies present a significant growth opportunity in the market.

• For instance, in May 2020, an article published by BJU International highlighted the potential of urology telehealth as a platform for providing clinical, financial, and environmental benefits to address the growing challenges associated with urological diseases.

Key Insights

The report covers the following key insights:

• Prevalence of Key Urological Diseases, By Key Countries/Region, 2023
• Key Industry Developments (Mergers, Acquisitions, Partnerships)
• Pipeline Analysis, By Key Players
• Impact of COVID-19 on the Market 

Segmentation

Analysis by Type

Based on type, the market is segmented into microscopic hematuria, gross hematuria, idiopathic hematuria, and others.

The microscopic hematuria segment is growing in the market due to increasing awareness of visible blood in urine, prompting faster medical intervention. The rising prevalence of urinary tract and kidney conditions including microscopic hematuria, coupled with advancements in diagnostic techniques, is driving the demand for treatments, thereby boosting the segment growth.

• For instance, in October 2020, an article published by the American Urological Association Education and Research, Inc. stated that the prevalence of microscopic hematuria reportedly varies from 2.4% to 31.1%.

Analysis by Indication

By indication, the market for hematuria treatment is subdivided into UTI, kidney stones, tumor in kidney or bladder, and benign prostate enlargement.

The UTI segment is anticipated to grow at a significant CAGR during the forecast timeframe. The growth is due to the rising cases of UTI especially in women and the growing demand for its treatment.

• For instance, according to an article published by BioMed Central Ltd in October 2023, a substantial majority of women, more than 50%, and a minimum of 12% of men will encounter a UTI at some point in their lives.

Benign prostate enlargement is more common in men and is anticipated to hold a substantial share of the market. 

Analysis by Drug Type

In terms of drug type, the market is segmented into antibiotics, diuretics, alpha-blockers, and others.

The antibiotics segment is expanding in the hematuria treatment market due to the rising incidence of urinary tract infections (UTIs), a common cause of hematuria. Increased awareness and early diagnosis of UTIs are driving the demand for antibiotics. Additionally, antibiotics are considered as the primary treatment for hematuria management and boosting market growth.

• For instance, an article published in November 2023 by NCBI, indicates that antibiotics such as Bactrim and Nitrofurantoin are considered the primary treatment options for UTIs. 

Analysis by Route of Administration

In terms of route of administration, the market is divided into two segments oral and parenteral.

The oral segment represents a significant market share. The segmental growth is due to the   convenience and patient preference for non-invasive options. The increasing availability of effective oral medications for underlying conditions, such as infections and inflammatory diseases, enhances patient compliance, driving product demand and contributing to the segment's expansion.

• For instance, in April 2024, the U.S. FDA approved Pivmecillinam by UTILITY Therapeutics, Ltd., an orally administered drug for the treatment of uncomplicated UTIs.

Analysis by Distribution Channel

In terms of distribution channel, the market for hematuria treatment is divided into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

The online pharmacies segment is anticipated to witness lucrative growth during the forecast period. This is due to new launches of online pharmacies providing discounts on these medicines and the convenience given to patients in terms of acquiring the medications.

• For instance, in November 2020, Amazon.com, Inc. launched Amazon Pharmacy, a full-service online pharmacy that provides easy access to a wide range of medications at affordable prices nationwide.

Regional Analysis

To gain extensive insights into the market, Download for Customization

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

The U.S. accounted for a significant share of the hematuria treatment market. This growth is due to the rising aging population, advanced healthcare infrastructure, and a high prevalence of kidney and urinary tract disorders, driving the demand for effective treatment options.

• For instance, in March 2024, the American Cancer Society estimated that there will be 63,070 men and 20,120 women that would suffer from bladder cancer.

Europe has a significant share of the market due to strong healthcare policies, increasing public awareness about urinary health, and significant investment in research and development, which is driving the availability of treatment options.

In India, the increasing prevalence of urinary tract infections and a growing population seeking advanced medical care, alongside improvements in diagnostic and treatment facilities across the country, is expected to drive the market growth.

• For instance, in October 2022, a report of a cross-sectional epidemiological study was published that revealed a prevalence rate of approximately 1.91% among otherwise healthy children in the North Indian population.

Key players

The report covers the profiles of the following key players:

• Pfizer Inc. (U.S.)
• Abbott (U.S.)
• Cipla (U.S.)
• SUN PHARMA (India)
• DR REDDY'S LABORATORIES LTD (India)
• Sanofi (France)
• Amneal Pharmaceuticals LLC (U.S)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Astellas Pharma Inc. (Japan)
• Lupin (India)

Key Industry Developments

• In November 2022, the U.S. FDA approved Amneal Pharmaceuticals LLC, an application of Leuprolide Acetate, an abbreviated drug injection for advanced prostate cancer, a condition in which Hematuria is a prevailing symptom.
• In December 2020, the U.S. FDA approved GEMTESA (vibegron) tablets by Urovant Sciences for the treatment of overactive bladder, where one of the symptoms is hematuria.